Prior exposure of 4T1 tumors to [neratinib + valproate] enhanced the expression of Class I MHCA and in parallel, reduced the expression of PD-L1; the reduced PD-L1 expression correlates to the enhanced anti-tumor efficacy of the anti-PD1 antibody administration (Figure 5B). The gene discussed is CD274; the disease is neoplasm.